18
Mar
2026
HIMS inked a deal with Novo Nordisk to bring the pharmaceutical drug to their practice within a week of regulatory backlash.
HIMS inks a deal with Novo Nordisk to bring the pharmaceutical drug to their practice and have a sole source agreement. So they set a landmine in the middle of all compounders.